2023 EULAR recommendations for the management of fatigue in people with inflammatory rheumatic and musculoskeletal diseases
Methodological detailsmultidisciplinary taskforce, two systematic reviews, Taskforce of 26 members from 14 European countries; recommendations based on systematic review of evidence supplemented with members' experience
- Multidisciplinary taskforce
- Two systematic reviews
- Taskforce of 26 members from 14 European countries; recommendations based on systematic review of evidence supplemented with members' experience
Recommendations
As issued by the authors
OAP: fatigue encompasses multiple biological, psychological and social factors which should inform clinical care
OAP: fatigue should be monitored and assessed, and people with inflammatory rheumatic and musculoskeletal diseases (I-RMDs) should be offered management options
Offer tailored physical activity and/or tailored psychoeducational interventions and/or, if clinically indicated, immunomodulatory treatment initiation or change
Patient-centred fatigue management should consider individual needs and preferences, clinical disease activity, comorbidities and other psychosocial and contextual factors through shared decision-making
Original publication
2023 EULAR recommendations for the management of fatigue in people with inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis. Published 30 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →